Focus:
Comment
-
11 November 2019
Healthline.com in rude health as it tops list of world’s most visited health-related websites
Healthline.com, owned by Healthline Media Inc, attracts over 200 million monthly visits, according to SimilarWeb.
-
8 November 2019
Keytruda overtakes Opdivo in the battle of PD-1 inhibitors
While Keytruda revenues grew an impressive 62% compared to Q3 2018 to reach $3.1m, Opdivo sales increased only by 1% compared to Q3 2018 to $1.8m.
-
7 November 2019
GSK’s booming Trelegy Ellipta sales indicate the strength of triple therapy combinations for COPD
The Glaxosmithkline headquarters office building in Brentford, London.
-
6 November 2019
AstraZeneca’s Farxiga continues to expand its therapeutic reach
AstraZeneca has targeted and continues to target multiple indications and related comorbidities to expand the therapeutic reach of Farxiga.
-
5 November 2019
Epidiolex’s first year: first FDA-approved anti-epileptic medical marijuana therapy
Epidiolex is a cannabidiol liquid extract, purified from medical-grade cannabis plants.
-
4 November 2019
2020 US drug expiries: big pharma set to feel the loss of major blockbusters
Novartis is set to suffer the greatest number of expiries in 2020 with eight drugs losing their market exclusivity.
-
4 November 2019
Robots are making significant inroads into surgery
GlobalData expects the medtech market to grow at a compound annual growth rate of 19% over the next three years.
-
1 November 2019
Partnerships with CDMOs will be a key growth driver for gene therapy
Companies that develop gene-based therapies often need to think in advance about how they want to develop a product, including the decision of whether to invest in a manufacturing facility...
-
1 November 2019
Next-gen pneumococcal vaccines: a race to the finish or a foregone conclusion?
Prophylactic vaccines come in two varieties: polysaccharide vaccines and pneumococcal conjugate vaccines.
-
1 November 2019
Highest proportion of eye cancer cases are among adults ages 60 years and older in the 7MM
There were over 7,000 diagnosed incident cases of primary eye cancer among men and women ages 20 years and older in the seven major markets in 2018.